Choose Language
Select a language for news translation.
Written by Prosper Junior Bakiny for The Motley Fool -> Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeuti…
Starbucks is stopping coverage of GLP-1 weight-loss drugs like Ozempic and Wegovy due to high costs, following a trend among large employers. This could limit …
The strength of its GLP-1 business suggests the stock still has more room to run.
CEO Brian Moynihan said he knows some employees will leave before reaping the health benefits.
Bank of America is spending over $250 million annually on GLP-1 weight loss drugs for its 211,000 employees, reflecting a strategic investment in employee heal…
As more people use Ozempic and other GLP-1s, coworkers are asking awkward questions about bodies and weight loss. Nobody knows where the line is.
Written by Prosper Junior Bakiny for The Motley Fool -> Expanding the GLP-1 market with new launches and label expansions will help Eli Lilly overcome increas…

























